Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

Eli Lilly and Company, a pharmaceutical manufacturing facility, will be receiving up to $100 million in performance-based ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Hyderabad: Pharma giant Eli Lilly and Company (India) opened its new technology and innovation centre in Hyderabad's Hitech ...